These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27813430)

  • 1. Fluzone® High-Dose Influenza Vaccine.
    Robertson CA; DiazGranados CA; Decker MD; Chit A; Mercer M; Greenberg DP
    Expert Rev Vaccines; 2016 Dec; 15(12):1495-1505. PubMed ID: 27813430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
    DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK
    N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
    Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review.
    Colrat F; Thommes E; Largeron N; Alvarez FP
    Vaccine; 2021 Mar; 39 Suppl 1():A42-A50. PubMed ID: 33518466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
    Chit A; Roiz J; Briquet B; Greenberg DP
    Vaccine; 2015 Jan; 33(5):734-41. PubMed ID: 25444791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis.
    Samson SI; Leventhal PS; Salamand C; Meng Y; Seet BT; Landolfi V; Greenberg D; Hollingsworth R
    Expert Rev Vaccines; 2019 Mar; 18(3):295-308. PubMed ID: 30689467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB
    Ann Pharmacother; 2021 Jan; 55(1):89-97. PubMed ID: 32578447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
    Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017-2018.
    Belongia EA; Levine MZ; Olaiya O; Gross FL; King JP; Flannery B; McLean HQ
    Vaccine; 2020 Mar; 38(15):3121-3128. PubMed ID: 32145994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
    Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
    Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
    Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Reactogenicity, and Health-Related Quality of Life After Trivalent Adjuvanted vs Trivalent High-Dose Inactivated Influenza Vaccines in Older Adults: A Randomized Clinical Trial.
    Schmader KE; Liu CK; Harrington T; Rountree W; Auerbach H; Walter EB; Barnett ED; Schlaudecker EP; Todd CA; Poniewierski M; Staat MA; Wodi P; Broder KR
    JAMA Netw Open; 2021 Jan; 4(1):e2031266. PubMed ID: 33443580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015-16 to 2018-19.
    Balasubramani GK; Choi WS; Nowalk MP; Zimmerman RK; Monto AS; Martin ET; Belongia EA; McLean HQ; Gaglani M; Murthy K; Jackson ML; Jackson LA; Chung JR; Spencer S; Fry AM; Patel M; Flannery B;
    Vaccine; 2020 Sep; 38(42):6562-6569. PubMed ID: 32800465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
    Chit A; Roiz J; Aballea S
    PLoS One; 2015; 10(7):e0133606. PubMed ID: 26222538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM; Dickey M; Graham I; Anderson EL; Noah DL; Hill H; Wolff M; Belshe RB
    Vaccine; 2015 Jan; 33(1):163-73. PubMed ID: 25444805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.